Evidence map›Paper›PMID 42535155›Full record

ArticleJournal of the anus, rectum and colon2026

Clinical Significance of Lymph Node Count in Colon Cancer Surgery: A Tumour Location-stratified Prognostic Analysis Based on an Integrated Phase-III Randomized Controlled Trial (JCOG2310AS3).

Kenta Iguchi, Kozo Kataoka, Junki Mizusawa, Akira Ouchi, Yusuke Sano, Fumihiko Fujita, Satoshi Maruyama, Kohei Murata, Yusuke Suwa, Kazuma Ito and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the anus, rectum and colon, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Kenta IguchiDepartment of Colorectal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Kozo KataokaDivision of Lower GI, Department of Gastroenterological Surgery, Hyogo Medical University, Hyogo, Japan.
Junki MizusawaJapan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Akira OuchiDepartment of Gastroenterological Surgery, Aichi Cancer Center Hospital, Aichi, Japan.
Yusuke SanoJapan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Fumihiko FujitaDepartment of Surgery, Kurume University School of Medicine, Kurume, Japan.
Satoshi MaruyamaDepartment of Gastrointestinal Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
Kohei MurataDepartment of Gastroenterological Surgery, Kansai Rosai Hospital, Amagasaki, Japan.
Yusuke SuwaDepartment of Surgery, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.
Kazuma ItoDivision of Lower GI, Department of Gastroenterological Surgery, Hyogo Medical University, Hyogo, Japan.
Takeshi SutoDepartment of Gastroenterological Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan.
Shin FujitaDepartment of Colorectal Surgery, Tochigi Cancer Center, Tochigi, Japan.
Ryo InadaDepartment of Gastroenterological Surgery, Kochi Health Sciences Center, Kochi, Japan.
Yasuhiro ShimadaClinical Oncology Division, Kochi Health Sciences Center, Kochi, Japan.
Masafumi InomataDepartment of Gastroenterological and Pediatric Surgery, Oita University Hospital, Oita, Japan.
Tetsuya HamaguchiDepartment of Gastroenterological Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
Yasumasa TakiiDepartment of Gastroenterological Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
Atsuo TakashimaDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Shunsuke TsukamotoDepartment of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.
Yukihide KanemitsuDepartment of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The prognostic significance of lymph node (LN) count in colon cancer (CC) remains controversial. Current guidelines recommend retrieval of ≥12 LNs for accurate staging; however, tumour sidedness may influence its prognostic relevance. This study evaluated the impact of LN count on survival according to tumour sidedness and pathological stage (pStage). Methods: This integrated analysis used data from randomised trials conducted by the Japan Clinical Oncology Group. Data from patients with pStage II/III CC who underwent curative resection were analysed. The prognostic significance of LN count was evaluated using Cox proportional hazards models for each subgroup consisting of a combination of tumour sidedness (right-sided CC [RSCC] vs. left-sided CC [LSCC]) and pStage. Results: A total of 2,849 patients (1,034 RSCC, 1,815 LSCC) were included. LN counts were higher in RSCC than in LSCC (median: 30 vs. 21). LN count was not independently associated with overall survival (OS) in pStage II. In contrast, in pStage III, lower LN counts were associated with worse OS on both tumour sides. In RSCC, thresholds of 9-14 (hazard ratio range: 0.17-0.50) and 26-41 (0.50-0.65) were associated with improved OS, whereas in LSCC, thresholds of 8-12 (0.34-0.61) were significant. Conclusion: Tumour sidedness and stage were associated with the prognostic impact of LN count in patients with pStage II/III CC. LN count showed limited prognostic impact in pStage II but was associated with survival in pStage III.

Indexed as

colon cancerlymph node countsurgerysurvivaltumour sidedness

Identifiers

PMID42535155
PMCPMC13423462

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.